Diplomat Pharmacy Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Diplomat Pharmacy Inc (DPLO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Diplomat Pharmacy Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 5,206M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.0% annualized vs trailing 12 months).
- Peer revenue share: Diplomat Pharmacy Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DPLO Sales vs. its Competitors, Q2 2019
Diplomat Pharmacy Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Pharmacy Services & Retail Drugstore industry grew revenue 6.7% year over year, combined, vs -5.3% for Diplomat Pharmacy Inc. Diplomat Pharmacy Inc's share of combined industry revenue moved from 0.34% to 0.30%, a loss of 0.04 percentage points.
Diplomat Pharmacy Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Diplomat Pharmacy Inc | No | No | Yes | No |
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DPLO Stock Performance relative to its Competitors
DPLO Stock Performance relative to Similar Growth & Profitability Competitors
Diplomat Pharmacy Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Diplomat Pharmacy Inc | Specialty Segment 95.56 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).